News >

Addressing PARP Inhibitor Resistance in Ovarian Cancer

Angelica Welch
Published: Monday, Jul 02, 2018

Kelly McCann, MD, PhD

Kelly McCann, MD, PhD
PARP inhibitors have made a substantial impact on the treatment of ovarian cancer in recent years. The DNA damage sensor PARP has wide-reaching roles in several pathways and processes of DNA repair, said Kelly McCann, MD, PhD. However, ovarian tumors continue to develop resistance to these therapies.

State of the Science Summit™ on Ovarian Cancer, McCann, a medical oncologist in the Breast Cancer Research Group at the University of California, Los Angeles, discussed the process of DNA damage and repair, resistance to PARP inhibitors, and rational combination strategies to overcome resistance.

Understanding DNA Damage

PARP1 and PARP2 both bind DNA at sites of damage, and they undergo a conformational change to activate their catalytic activity, McCann explained. The types of damage recognized are single-strand DNA breaks, DNA double-strand breaks, and DNA crosslinks, supercoils and stalled replication forks. When they bind to this kind of DNA damage, they use nicotinamide adenine dinucleotide (NAD+) as a substrate in order to add ADP ribose moieties onto the target proteins, added McCann. They add these in a linear fashion, as well as in chains in a process called PARylation.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication